CARGO Therapeutics

United States - San Mateo, California

• 06/03/2023
• Series A
• $200,000,000

CARGO Therapeutics is engineering best-in-class CAR T-cell therapy to overcome resistance to cancer treatment and address barriers to access so that more patients may benefit from potentially curative therapies. CARGO is on a mission to outsmart cancer by advancing a new generation of best-in-class chimeric antigen receptor (CAR) T-cell therapies. Despite advances made by commercially available autologous CARs, these treatments are curative for fewer than half of all cancer patients. In addition, far too many patients are unable to access these potentially curative therapies due to other challenges, including manufacturing, supply constraints, slow turnaround time and reimbursement hurdles. The team at CARGO is intensely focused on pursuing novel solutions to achieve better cancer treatment outcomes and experiences.

Related People

Gina Simmons ChapmaFounder

United States - San Francisco Bay Area

Biotechnology and pharmaceutical leader with 30 years of commercial and operational experience across numerous therapeutic areas, with a track record of success building strong teams and organizations, shaping strategy and delivering exceptional results. I am passionate about relentlessly pursuing better outcomes and experiences for people with cancer and rare diseases, and as CEO for CARGO Therapeutics I am honored to be a part of a talented and experienced team that is outsmarting cancer by leveraging a deep understanding of resistance and novel technologies to raise the bar for what CAR-T cell therapies can achieve for patients.

At CARGO Therapeutics we are boldly pursuing our mission to enhance the efficacy of CAR-T cell therapeutics with next generation platforms designed to solve the problems of resistance and access so that more people with cancer live longer lives. We are building something special and we are hiring: https://CARGO-tx.com/#careers

LinkedIn https://www.linkedin.com/in/gina-simmons-chapman/